By maximizing clinical and economic benefits through precision-guided patient selection, dupilumab’s dual IL-4/IL-13 blockade makes it a versatile biologic—especially suited for T2-high and overlapping asthma phenotypes or patients with comorbidities such as nasal polyps, eosinophilic esophagitis, and atopic dermatitis. The gene discussed is IL13; the disease is atopic eczema.